AU2002334844B2 - Adjuvanted meningococcus compositions - Google Patents

Adjuvanted meningococcus compositions Download PDF

Info

Publication number: AU2002334844B2
Authority: AU; Australia
Prior art keywords: composition; antigen; plg; protein; cpg
Prior art date: 2001-10-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU2002334844A

Other languages

English (en)

Other versions

AU2002334844A1 (en

AU2002334844B8 (en

Inventor

Derek O'hagan

Nicholas Valiante

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis Vaccines and Diagnostics Inc

Original Assignee

Chiron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-03

Filing date

2002-10-03

Publication date

2007-08-02

2002-04-05 Priority claimed from PCT/US2002/010869 external-priority patent/WO2002080648A2/fr

2002-10-03 Application filed by Chiron Corp filed Critical Chiron Corp

2003-04-14 Application granted granted Critical

2003-04-14 Publication of AU2002334844B8 publication Critical patent/AU2002334844B8/en

2003-06-26 Publication of AU2002334844A1 publication Critical patent/AU2002334844A1/en

2007-08-02 Publication of AU2002334844B2 publication Critical patent/AU2002334844B2/en

2007-10-26 Priority to AU2007231677A priority Critical patent/AU2007231677A1/en

2008-11-27 Assigned to NOVARTIS VACCINES AND DIAGNOSTICS, INC. reassignment NOVARTIS VACCINES AND DIAGNOSTICS, INC. Alteration of Name(s) in Register under S187 Assignors: CHIRON CORPORATION

2022-10-03 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims description 84
108091007433 antigens Proteins 0.000 claims description 150
102000036639 antigens Human genes 0.000 claims description 150
239000000427 antigen Substances 0.000 claims description 136
239000011859 microparticle Substances 0.000 claims description 82
108090000623 proteins and genes Proteins 0.000 claims description 58
102000004169 proteins and genes Human genes 0.000 claims description 56
239000002671 adjuvant Substances 0.000 claims description 37
108091034117 Oligonucleotide Proteins 0.000 claims description 32
241001212279 Neisseriales Species 0.000 claims description 24
238000000034 method Methods 0.000 claims description 18
241000124008 Mammalia Species 0.000 claims description 14
241000588650 Neisseria meningitidis Species 0.000 claims description 13
229920002988 biodegradable polymer Polymers 0.000 claims description 10
239000004621 biodegradable polymer Substances 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 10
208000015181 infectious disease Diseases 0.000 claims description 10
230000000844 anti-bacterial effect Effects 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
230000028993 immune response Effects 0.000 claims description 8
201000010099 disease Diseases 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 6
230000005875 antibody response Effects 0.000 claims description 4
230000002163 immunogen Effects 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
239000005547 deoxyribonucleotide Substances 0.000 claims 1
125000002637 deoxyribonucleotide group Chemical group 0.000 claims 1
CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 76
235000018102 proteins Nutrition 0.000 description 50
229940037003 alum Drugs 0.000 description 25
229960005486 vaccine Drugs 0.000 description 22
238000001179 sorption measurement Methods 0.000 description 17
229920000642 polymer Polymers 0.000 description 14
238000007918 intramuscular administration Methods 0.000 description 11
150000001720 carbohydrates Chemical class 0.000 description 10
238000009472 formulation Methods 0.000 description 10
108020004707 nucleic acids Proteins 0.000 description 10
102000039446 nucleic acids Human genes 0.000 description 10
150000007523 nucleic acids Chemical class 0.000 description 10
239000003599 detergent Substances 0.000 description 9
239000000839 emulsion Substances 0.000 description 9
239000002245 particle Substances 0.000 description 9
239000008194 pharmaceutical composition Substances 0.000 description 8
-1 polysaccharide oligosaccharides Chemical class 0.000 description 8
241000700605 Viruses Species 0.000 description 7
238000002649 immunization Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
229940079593 drug Drugs 0.000 description 6
230000000694 effects Effects 0.000 description 6
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
229940035032 monophosphoryl lipid a Drugs 0.000 description 5
239000000725 suspension Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 4
201000005702 Pertussis Diseases 0.000 description 4
206010043376 Tetanus Diseases 0.000 description 4
229920001577 copolymer Polymers 0.000 description 4
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
206010013023 diphtheria Diseases 0.000 description 4
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 4
229920001542 oligosaccharide Polymers 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
238000011282 treatment Methods 0.000 description 4
TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 3
JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
108010039939 Cell Wall Skeleton Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000588653 Neisseria Species 0.000 description 3
239000004372 Polyvinyl alcohol Substances 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229910021502 aluminium hydroxide Inorganic materials 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
239000000969 carrier Substances 0.000 description 3
210000004520 cell wall skeleton Anatomy 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
150000002482 oligosaccharides Chemical class 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
239000005017 polysaccharide Substances 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
229920002451 polyvinyl alcohol Polymers 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000001397 quillaja saponaria molina bark Substances 0.000 description 3
229930182490 saponin Natural products 0.000 description 3
150000007949 saponins Chemical class 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 2
102100034452 Alternative prion protein Human genes 0.000 description 2
241000588832 Bordetella pertussis Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
108010065805 Interleukin-12 Proteins 0.000 description 2
108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 2
241000588677 Neisseria meningitidis serogroup B Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
108091093037 Peptide nucleic acid Proteins 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
125000003275 alpha amino acid group Chemical group 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
229940001007 aluminium phosphate Drugs 0.000 description 2
229940077746 antacid containing aluminium compound Drugs 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
229960003964 deoxycholic acid Drugs 0.000 description 2
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
150000002772 monosaccharides Chemical group 0.000 description 2
SBWGZAXBCCNRTM-CTHBEMJXSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]octanamide Chemical compound CCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SBWGZAXBCCNRTM-CTHBEMJXSA-N 0.000 description 2
229940066429 octoxynol Drugs 0.000 description 2
229920002113 octoxynol Polymers 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
229920001432 poly(L-lactide) Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
238000010845 search algorithm Methods 0.000 description 2
238000000935 solvent evaporation Methods 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000001694 spray drying Methods 0.000 description 2
229940031439 squalene Drugs 0.000 description 2
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 2
239000012646 vaccine adjuvant Substances 0.000 description 2
229940124931 vaccine adjuvant Drugs 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
ZWEVPYNPHSPIFU-AUGHYPCGSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxy-n-[3-[3-[[(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoyl]amino]propyl-[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenan Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)N(CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C)[C@@]2(C)[C@@H](O)C1 ZWEVPYNPHSPIFU-AUGHYPCGSA-N 0.000 description 1
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
NKOTXYPTXKUCDL-UHFFFAOYSA-N 4-(trifluoromethyl)pyrimidin-2-amine Chemical compound NC1=NC=CC(C(F)(F)F)=N1 NKOTXYPTXKUCDL-UHFFFAOYSA-N 0.000 description 1
101710115267 ATP synthase protein MI25 Proteins 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
101100214875 Autographa californica nuclear polyhedrosis virus p95 gene Proteins 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241001118702 Border disease virus Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
101100039010 Caenorhabditis elegans dis-3 gene Proteins 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
241001155433 Centrarchus macropterus Species 0.000 description 1
CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
239000004380 Cholic acid Substances 0.000 description 1
102100031725 Cortactin-binding protein 2 Human genes 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
241000710829 Dengue virus group Species 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
KTNROWWHOBZQGK-UHFFFAOYSA-N Etilefrine hydrochloride (TN) Chemical compound [Cl-].CC[NH2+]CC(O)C1=CC=CC(O)=C1 KTNROWWHOBZQGK-UHFFFAOYSA-N 0.000 description 1
241000710781 Flaviviridae Species 0.000 description 1
241000710831 Flavivirus Species 0.000 description 1
101710112524 GDP-mannose transporter 2 Proteins 0.000 description 1
108010007979 Glycocholic Acid Proteins 0.000 description 1
108010035713 Glycodeoxycholic Acid Proteins 0.000 description 1
WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 description 1
101150029115 HOPX gene Proteins 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
241000590002 Helicobacter pylori Species 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
101000833492 Homo sapiens Jouberin Proteins 0.000 description 1
101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 1
241000702617 Human parvovirus B19 Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
241000710842 Japanese encephalitis virus Species 0.000 description 1
102100024407 Jouberin Human genes 0.000 description 1
241001082241 Lythrum hyssopifolia Species 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
206010027202 Meningitis bacterial Diseases 0.000 description 1
238000010629 Molecular evolutionary genetics analysis Methods 0.000 description 1
241000588655 Moraxella catarrhalis Species 0.000 description 1
208000005647 Mumps Diseases 0.000 description 1
101100476480 Mus musculus S100a8 gene Proteins 0.000 description 1
RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
241001644525 Nastus productus Species 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
241000588649 Neisseria lactamica Species 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
101150075249 ORF40 gene Proteins 0.000 description 1
101150004576 ORF83 gene Proteins 0.000 description 1
101100317123 Orgyia pseudotsugata multicapsid polyhedrosis virus GP41 gene Proteins 0.000 description 1
101100156835 Paenarthrobacter nicotinovorans xdh gene Proteins 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
108010081690 Pertussis Toxin Proteins 0.000 description 1
241000710778 Pestivirus Species 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
241000605862 Porphyromonas gingivalis Species 0.000 description 1
241000288906 Primates Species 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
101710088555 Probable GDP-mannose transporter 2 Proteins 0.000 description 1
101710197985 Probable protein Rev Proteins 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010037742 Rabies Diseases 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
241000193985 Streptococcus agalactiae Species 0.000 description 1
101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
241000710771 Tick-borne encephalitis virus Species 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
101710134973 Uncharacterized 9.7 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
206010051511 Viral diarrhoea Diseases 0.000 description 1
241000710886 West Nile virus Species 0.000 description 1
241000710772 Yellow fever virus Species 0.000 description 1
KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
150000001399 aluminium compounds Chemical class 0.000 description 1
159000000013 aluminium salts Chemical class 0.000 description 1
229910000329 aluminium sulfate Inorganic materials 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940065181 bacillus anthracis Drugs 0.000 description 1
201000009904 bacterial meningitis Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
SXPWTBGAZSPLHA-UHFFFAOYSA-M cetalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SXPWTBGAZSPLHA-UHFFFAOYSA-M 0.000 description 1
229960000228 cetalkonium chloride Drugs 0.000 description 1
229940038705 chlamydia trachomatis Drugs 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
235000019416 cholic acid Nutrition 0.000 description 1
229960002471 cholic acid Drugs 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
238000005354 coacervation Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
238000002050 diffraction method Methods 0.000 description 1
CSNHNGDROQRZKT-DSVPTQILSA-M dimethyl-[(2,3,4,5,6-pentadeuteriophenyl)methyl]-tetradecylazanium bromide Chemical compound [Br-].C(C1=C(C(=C(C(=C1[2H])[2H])[2H])[2H])[2H])[N+](CCCCCCCCCCCCCC)(C)C CSNHNGDROQRZKT-DSVPTQILSA-M 0.000 description 1
229960003983 diphtheria toxoid Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 description 1
238000002296 dynamic light scattering Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000001879 gelation Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
229940099347 glycocholic acid Drugs 0.000 description 1
WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
229940037467 helicobacter pylori Drugs 0.000 description 1
229930186900 holotoxin Natural products 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
229960005225 mifamurtide Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000001459 mortal effect Effects 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
208000010805 mumps infectious disease Diseases 0.000 description 1
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
UMWKZHPREXJQGR-UHFFFAOYSA-N n-methyl-n-(2,3,4,5,6-pentahydroxyhexyl)decanamide Chemical compound CCCCCCCCCC(=O)N(C)CC(O)C(O)C(O)C(O)CO UMWKZHPREXJQGR-UHFFFAOYSA-N 0.000 description 1
UMWKZHPREXJQGR-XOSAIJSUSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]decanamide Chemical compound CCCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO UMWKZHPREXJQGR-XOSAIJSUSA-N 0.000 description 1
GCRLIVCNZWDCDE-SJXGUFTOSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]nonanamide Chemical compound CCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO GCRLIVCNZWDCDE-SJXGUFTOSA-N 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
108010021711 pertactin Proteins 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
239000002745 poly(ortho ester) Substances 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
239000004632 polycaprolactone Substances 0.000 description 1
229940051841 polyoxyethylene ether Drugs 0.000 description 1
229920000056 polyoxyethylene ether Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000004044 response Effects 0.000 description 1
201000005404 rubella Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
VMSNAUAEKXEYGP-YEUHZSMFSA-M sodium glycodeoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 VMSNAUAEKXEYGP-YEUHZSMFSA-M 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
229940045946 sodium taurodeoxycholate Drugs 0.000 description 1
YXHRQQJFKOHLAP-FVCKGWAHSA-M sodium;2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 YXHRQQJFKOHLAP-FVCKGWAHSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
229940032094 squalane Drugs 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
229940032085 sucrose monolaurate Drugs 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940051021 yellow-fever virus Drugs 0.000 description 1
PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Microbiology (AREA)
Virology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Mycology (AREA)
Tropical Medicine & Parasitology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Biological Depolymerization Polymers (AREA)
Compositions Of Macromolecular Compounds (AREA)

AU2002334844A 2001-10-03 2002-10-03 Adjuvanted meningococcus compositions Ceased AU2002334844B2 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
AU2007231677A AU2007231677A1 (en)	2001-10-03	2007-10-26	Adjuvanted meningococcus compositions

Applications Claiming Priority (15)

Application Number	Priority Date	Filing Date	Title
US32692901P	2001-10-03	2001-10-03
US60/326,929		2001-10-03
PCT/US2002/010869 WO2002080648A2 (fr)	2001-04-05	2002-04-05	Augmentation de l'immunite des muqueuses a la suite d'un amorçage parenteral
USPCT/US02/10869		2002-04-05
US37354702P	2002-04-17	2002-04-17
US60/373,547		2002-04-17
US38067702P	2002-05-13	2002-05-13
US60/380,677		2002-05-13
US25443802A	2002-09-24	2002-09-24
USPCT/US02/30423		2002-09-24
US10/254,438		2002-09-24
US0230423		2002-09-24
US10/265,083		2002-10-03
AU2002332019		2002-10-03
PCT/US2002/031726 WO2003028661A2 (fr)	2001-10-03	2002-10-03	Compositions de meningocoque assorties d'un adjuvant

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2007231677A Division AU2007231677A1 (en)	2001-10-03	2007-10-26	Adjuvanted meningococcus compositions

Publications (3)

Publication Number	Publication Date
AU2002334844B8 AU2002334844B8 (en)	2003-04-14
AU2002334844A1 AU2002334844A1 (en)	2003-06-26
AU2002334844B2 true AU2002334844B2 (en)	2007-08-02

Family

ID=32601151

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002334844A Ceased AU2002334844B2 (en)	2001-10-03	2002-10-03	Adjuvanted meningococcus compositions

Country Status (8)

Country	Link
EP (1)	EP1438323A4 (fr)
JP (1)	JP4522699B2 (fr)
CN (1)	CN100354297C (fr)
AU (1)	AU2002334844B2 (fr)
BR (1)	BR0213119A (fr)
CA (1)	CA2462646C (fr)
NZ (1)	NZ532274A (fr)
WO (1)	WO2003028661A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
MXPA04011249A (es) *	2002-05-14	2005-06-06	Chiron Srl	Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0302218D0 (en)	2003-01-30	2003-03-05	Chiron Sri	Vaccine formulation & Mucosal delivery
DK2255826T3 (en) *	2002-08-02	2016-06-20	Glaxosmithkline Biologicals Sa	Neisserial vaccine compositions comprising a combination of antigens.
WO2004060396A2 (fr)	2002-12-27	2004-07-22	Chiron Corporation	Immunogenes contenant des compositions de phospholipide
ATE426412T1 (de) *	2003-01-30	2009-04-15	Novartis Vaccines & Diagnostic	Adjuvante influenza-vakzine
PT2172213E (pt) *	2003-01-30	2013-06-03	Novartis Ag	Vacinas injetáveis contra múltiplos serogrupos meningocócicos
US7731967B2 (en)	2003-04-30	2010-06-08	Novartis Vaccines And Diagnostics, Inc.	Compositions for inducing immune responses
CA2528007C (fr)	2003-06-02	2012-03-27	Chiron Corporation	Compositions immunogenes basees sur des microparticules comprenant des antigenes contenant de l'anatoxine adsorbee et des polysaccharides
US20050222072A1 (en) *	2004-02-20	2005-10-06	Hybridon, Inc.	Potent mucosal immune response induced by modified immunomodulatory oligonucleotides
EP1812056B1 (fr)	2004-11-15	2013-08-07	Novartis Vaccines and Diagnostics, Inc.	Compositions immunogenes contenant un antigene de l'anthrax, des microparticules de polymeres biodegradables, et un adjuvant immunologique contenant un polynucleotide
CN107261127A (zh)	2005-01-28	2017-10-20	盖伦生物公司	免疫活性组合物
JP2008531672A (ja) *	2005-03-02	2008-08-14	イギリス国	医薬組成物
EP3067048B1 (fr)	2007-12-07	2018-02-14	GlaxoSmithKline Biologicals SA	Compositions d'induction des réponses immunitaires
CN101559225B (zh) *	2008-04-18	2012-07-11	北京生物制品研究所	脑膜炎球菌疫苗
KR20250052503A (ko)	2012-06-21	2025-04-18	노쓰웨스턴유니버시티	펩티드 접합된 입자

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000050075A2 (fr) *	1999-02-26	2000-08-31	Chiron S.P.A.	Developpement de l'activite bactericide des antigenes de neisseria a l'aide d'oligonucleotides a motifs cg

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
ATE476508T1 (de) *	1997-11-06	2010-08-15	Novartis Vaccines & Diagnostic	Neisseriale antigene
SG152917A1 (en) *	1998-01-14	2009-06-29	Chiron Srl	Neisseria meningitidis antigens
EP2261341A3 (fr) *	1998-05-01	2012-01-04	Novartis Vaccines and Diagnostics, Inc.	Antigènes de Neisseria meningitidis et compositions
ATE321535T1 (de) *	1998-07-29	2006-04-15	Chiron Corp	Mikropartikel mit adsorbenten oberflächen, verfahren zu ihrer herstellung und ihrer verwendung
CN1338005A (zh) *	1998-10-09	2002-02-27	希龙公司	奈瑟球菌基因组序列及其用途
JP2002537102A (ja) *	1999-02-26	2002-11-05	カイロンコーポレイション	吸着された高分子および微粒子を有するミクロエマルジョン
EP1228217B1 (fr) *	1999-04-30	2012-11-21	Novartis Vaccines and Diagnostics S.r.l.	Antigenes de neisseria conserves
CN101139590B (zh) *	2000-02-28	2012-07-18	启龙股份公司	奈瑟球菌蛋白质的杂交表达

2002
- 2002-10-03 CN CNB028241282A patent/CN100354297C/zh not_active Expired - Fee Related
- 2002-10-03 AU AU2002334844A patent/AU2002334844B2/en not_active Ceased
- 2002-10-03 CA CA2462646A patent/CA2462646C/fr not_active Expired - Fee Related
- 2002-10-03 JP JP2003531997A patent/JP4522699B2/ja not_active Expired - Fee Related
- 2002-10-03 BR BR0213119-6A patent/BR0213119A/pt not_active IP Right Cessation
- 2002-10-03 NZ NZ532274A patent/NZ532274A/en not_active IP Right Cessation
- 2002-10-03 WO PCT/US2002/031726 patent/WO2003028661A2/fr not_active Ceased
- 2002-10-03 EP EP02800481A patent/EP1438323A4/fr not_active Withdrawn

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000050075A2 (fr) *	1999-02-26	2000-08-31	Chiron S.P.A.	Developpement de l'activite bactericide des antigenes de neisseria a l'aide d'oligonucleotides a motifs cg

Also Published As

Publication number	Publication date
CN100354297C (zh)	2007-12-12
JP2005526697A (ja)	2005-09-08
WO2003028661A3 (fr)	2003-10-09
CN1599746A (zh)	2005-03-23
JP4522699B2 (ja)	2010-08-11
WO2003028661A2 (fr)	2003-04-10
EP1438323A4 (fr)	2007-08-01
EP1438323A2 (fr)	2004-07-21
NZ532274A (en)	2006-02-24
BR0213119A (pt)	2004-12-28
AU2002334844B8 (en)	2003-04-14
CA2462646C (fr)	2013-02-12
CA2462646A1 (fr)	2003-04-10

Publication	Publication Date	Title
USRE45137E1 (en)	2014-09-16	Adjuvanted meningococcus compositions
CA2452720C (fr)	2012-04-17	Vaccins comprenant des adjuvants aluminium et histidine
US7348006B2 (en)	2008-03-25	Vaccines comprising aluminium adjuvants and histidine
EP1587538B1 (fr)	2014-04-02	Vaccins contre le meningocoque administres par la muqueuse
US20110150923A1 (en)	2011-06-23	Mucosal meningococcal vaccines
AU2002334844B8 (en)	2003-04-14	Adjuvanted meningococcus compositions
AU2002330681A1 (en)	2003-05-29	Vaccines comprising aluminium adjuvants and histidine
JP2017178971A (ja)	2017-10-05	血清型ＢおよびＣ由来のＮｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ抗原、ならびにさらなる抗原を含む組成物
AU2002334844A1 (en)	2003-06-26	Adjuvanted meningococcus compositions
US7838015B2 (en)	2010-11-23	Adjuvanted meningococcus compositions
AU2007231677A1 (en)	2007-11-22	Adjuvanted meningococcus compositions
RU2360699C2 (ru)	2009-07-10	Композиции менингококковых вакцин с адъювантами
MXPA04003186A (es)	2004-07-08	Composiciones de meningococo coadyuvantes.

Legal Events

Date	Code	Title	Description
2007-08-23	TH	Corrigenda	Free format text: IN VOL 21, NO 30, PAGE(S) 3511 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME CHIRON CORPORATION, APPLICATION NO. 2002334844, UNDER INID (30), CORRECT THE PRIORITY DETAIL TO READ PCT/US02/10869 US 5 APR 2002; 60/380,677 US 13 MAY 2002; PCT/US02/30423 US 24 SEP 2002; 10/265,083 US 3 OCT 2002; 60/373,547 US 17 APR 2002; 60/326,929 US 3 OCT 2001: 10/254,438 US 24 SEP 2002; PCT/US02/31486 US 3 OCT 2002
2007-12-06	FGA	Letters patent sealed or granted (standard patent)
2014-05-01	MK14	Patent ceased section 143(a) (annual fees not paid) or expired